Revolution Medicines' KRAS drug shows promise
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Revolution Medicines reported positive results for its KRAS inhibitor daraxonrasib in pancreatic cancer patients, suggesting the first effective oral KRAS therapy.
- Novo Nordisk achieved its Phase 3 endpoints with the oral drug etavopivat, lowering pain crisis risk and improving hemoglobin in sickle‑cell disease patients.
- Eli Lilly is finalizing a $2 billion‑plus acquisition of Kelonia Therapeutics, adding an in‑vivo CAR‑T platform for multiple myeloma.
Why it matters: Eli Lilly’s $2 billion purchase of Kelonia gives the drugmaker a ready‑made in‑vivo CAR‑T platform, boosting its oncology pipeline and hastening the launch of off‑the‑shelf cell therapies for multiple myeloma.
Ask SkimNews
